ZANTAC 25
LOE ApproachingNDAORALTABLET, EFFERVESCENT
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 25 is an oral effervescent tablet approved in 1994 as an NDA by GSK. The generic mechanism of action and specific indications are not provided in available data, limiting clinical characterization.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team likely focused on transition strategy and generic preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring and limited career expansion opportunities on this product. Working on ZANTAC 25 offers stability but little growth trajectory as the product approaches loss of exclusivity.
Brand ManagerProduct Manager
Worked on ZANTAC 25 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.